Influenza vaccines. The good, the bad, and the eggs

Advances in Virus Research

Volumn 77, Issue C, 2010, Pages 63-84

  Schultz Cherry, Stacey ^a   Jones, Jeremy C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ANIMAL; BIOSYNTHESIS; BOOK; EPIDEMIC; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; RESPIRATORY TRACT INFECTION; UNITED STATES; VACCINATION; VIROLOGY; DISEASE OUTBREAKS; EPIDEMIOLOGY; INFLUENZA, HUMAN;

ANIMALS; DISEASE OUTBREAKS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; RESPIRATORY TRACT INFECTIONS; UNITED STATES; VACCINATION;

EID: 77958193069     PISSN: 00653527     EISSN: 15578399     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385034-8.00003-X     Document Type: Book

References (160)

1. Altstein A.D., et al. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch. Virol. 2006, 151:921-931.
2. Anonymous Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. Wkly. Epidemiol. Rec. 2010, 85:81-92.
3. Anonymous Update on human cases of highly pathogenic avian influenza A (H5N1) infection: 2009. Wkly Epidemiol. Rec. 2010, 85:49-51.
4. Anonymous Summary of human infection with highly pathogenic avian influenza A (H5N1) virus reported to WHO, January 2003-March 2009: Cluster-associated cases. Wkly. Epidemiol. Rec. 2010, 85:13-20.
5. Anonymous Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines-February 2010. Wkly. Epidemiol. Rec. 2010, 85:100-107.
6. Atmar R.L., Keitel W.A. Adjuvants for pandemic influenza vaccines. Curr. Top. Microbiol. Immunol. 2009, 333:323-344.
7. Atmar R.L., et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis. 2006, 43:1135-1142.
8. Azziz-Baumgartner E., et al. National pandemic influenza preparedness planning. Influenza Other Respi. Viruses 2009, 3:189-196.
9. Baldridge J.R., et al. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 2000, 18:2416-2425.
10. Baldwin S.L., et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27:5956-5963.
11. Banzhoff A., et al. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respi. Viruses 2008, 2:243-249.
12. Barker W.H., Mullooly J.P. Impact of epidemic type A influenza in a defined adult population. Am. J. Epidemiol. 1980, 112:798-811.
13. Baylor N.W., Houn F. Considerations for licensure of influenza vaccines with pandemic and prepandemic indications. Curr. Top. Microbiol. Immunol. 2009, 333:453-470.
14. Belshe R.B. Influenza as a zoonosis: How likely is a pandemic?. Lancet 1998, 351:460-461.
15. Benhamou A.H., et al. State of the art and new horizons in the diagnosis and management of egg allergy. Allergy 2010, 65:283-289.
16. Brands R., et al. Influvac: A safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. Dev. Biol. Stand. 1999, 98:93-100. discussion 111.
17. Butler D. Vaccine decisions loom for new flu strain. Nature 2009, 459:144-145.
18. Butt K.M., et al. Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J. Clin. Microbiol. 2005, 43:5760-5767.
19. CDC Influenza: The disease http://www.cdc.gov/flu/about/disease.htm.
20. CDC Key facts about seasonal flu vaccine http://www.cdc.gov/flu/protect/keyfacts.htm.
21. CDC Flu season summary http://www.cdc.gov/flu/weekly/weeklyarchives2007-2008/07-08summary.htm.
22. CDC Outbreak of swine-origin influenza A (H1N1) virus infection-Mexico, March-April 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 58:467-470.
23. CDC Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 58:400-402.
24. CDC Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb. Mortal. Wkly. Rep. 2009, 58:521-524.
25. CDC Use of influenza A (H1N1) 2009 monovalent vaccine. MMWR 2009, 58:1-8.
26. Chan M. World now at the start of 2009 influenza pandemic http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/.
27. Chan M.C., et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir. Res. 2005, 6:135.
28. Cheung C.Y., et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet 2002, 360:1831-1837.
29. Chotpitayasunondh T., et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg. Infect. Dis. 2005, 11:201-209.
30. Claas E.C., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351:472-477.
31. Collin N., de Radiguès X. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza. Vaccine 2009, 27:5184-5186.
32. Conenello G.M., Palese P. Influenza A virus PB1-F2: A small protein with a big punch. Cell Host Microbe 2007, 2:207-209.
33. Cooper C.L., et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004, 22:3136-3143.
34. Cox R.J., et al. Influenza virus: Immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 2004, 59:1-15.
35. Crowe J.E. Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches. Vaccine 2009, 27:G47-G51.
36. Deng G., et al. Acute respiratory distress syndrome induced by H9N2 virus in mice. Arch. Virol. 2010, 155:187-195.
37. Dormitzer P.R., et al. Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. PLoS Curr. Influenza 2009, Aug. 31 RRN1025.
38. Doroshenko A., Halperin S.A. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev. Vaccines 2009, 8:679-688.
39. Du L., et al. Research and development of universal influenza vaccines. Microbes Infect. 2010, 12:280-286.
40. Ehrlich H.J., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 2008, 358:2573-2584.
41. Ekiert D.C., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.
42. Ellebedy A.H., Webby R.J. Influenza vaccines. Vaccine 2009, 27(Suppl. 4):D65-D68.
43. Fritz J.H., et al. The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens. Vaccine 2004, 22:3274-3284.
44. Garten R.J., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) Influenza viruses circulating in humans. Science 2009, 325:197-201.
45. Genzel Y., Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev. Vaccines 2009, 8:1681-1692.
46. Girard M.P., et al. A review of vaccine research and development: Human acute respiratory infections. Vaccine 2005, 23(50):5708-5724.
47. Glinsky G.V. Genomic analysis of pandemic (H1N1) 2009 reveals association of increasing disease severity with emergence of novel hemagglutinin mutations. Cell Cycle 2010, 9:958-970.
48. Greenberg M.E., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N. Engl. J. Med. 2009, 361:2405-2413.
49. Gregoriades A., Frangione B. Insertion of influenza M protein into the viral lipid bilayer and localization of site of insertion. J. Virol. 1981, 40:323-328.
50. Guan Y., et al. Molecular characterization of H9N2 influenza viruses: Were they the donors of the "internal" genes of H5N1 viruses in Hong Kong?. Proc. Natl. Acad. Sci. USA 1999, 96:9363-9367.
51. Guan Y., et al. Molecular epidemiology of H5N1 avian influenza. Rev. Sci. Tech. 2009, 28:39-47.
52. Hancock K., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 2009, 361:1945-1952.
53. Hehme N., et al. Pandemic preparedness: Lessons learnt from H2N2 and H9N2 candidate vaccines. Med. Microbiol. Immunol. 2002, 191:203-208.
54. Horimoto T., Kawaoka Y. Influenza: Lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 2005, 3:591-600.
55. Hossain M.J., et al. Evidence of expanded host range and mammalian-associated genetic changes in a duck H9N2 influenza virus following adaptation in quail and chickens. PLoS ONE 2008, 3:e3170.
56. Ichinohe T., et al. PolyI:Polyc12u adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine 2009, 27:6276-6279.
57. Ilyushina N.A., Kim J.K., Negovetich N.J., Choi Y.K., Lang V., Bovin N.V., Forrest H.L., Song M.S., Pascua P., Kim C.J., Webster R.G., Webby R.J. Extensive mammalian ancestry of pandemic (H1N1) 2009 virus. Emerg. Infect. Dis. 2010, 16:314-317.
58. Ito T., Kawaoka Y. Host-range barrier of influenza A viruses. Vet. Microbiol. 2000, 74:71-75.
59. Jain S., et al. Hospitalized Patients with 2009 H1N1 Influenza in the United States, April-June 2009. N. Engl. J. Med. 2009, 361:1935-1944.
60. Karron R.A., et al. A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J. Infect. Dis. 2009, 199:711-716.
61. Kash J.C., et al. Prior infection with classical swine H1N1 influenza viruses is associated with protective immunity to the 2009 pandemic H1N1 virus. Influenza Other Respi. Viruses 2010, 4:121-127.
62. Katz J.M., et al. Pathogenesis of and immunity to avian influenza A H5 viruses. Biomed. Pharmacother. 2000, 54:178-187.
63. Keitel W.A., Atmar R.L. Vaccines for pandemic influenza: Summary of recent clinical trials. Curr. Top. Microbiol. Immunol. 2009, 333:431-451.
64. Keitel W., et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010, 28:840-848.
65. Kelly H., Barr I. Large trials confirm immunogenicity of H1N1 vaccines. Lancet 2010, 375:6-9.
66. Kistner O., Barrett P.N., Mundt W., Reiter M., Schober-Bendixen S., Eder G., Dorner F. Development of a Vero cell-derived influenza whole virus vaccine. Dev. Biol. Stand. 1999, 98:101-110.
67. Krauss S., et al. Influenza A viruses of migrating wild aquatic birds in North America. Vector Borne Zoonotic Dis. 2004, 4:177-189.
68. Krug R.M., et al. Intracellular warfare between human influenza viruses and human cells: The roles of the viral NS1 protein. Virology 2003, 309:181-189.
69. Lamb R.A., Krug R.M. Orthomyxoviridae: The viruses and their replication. Fields Virology 2001, vol 1:1487-1531. Lippincott Williams & Wilkins, Philadelphia. 4th edn. D.M. Knipe (Ed.).
70. Lee D., et al. Differential replication of avian influenza H9N2 viruses in human alveolar epithelial A549 cells. Virol. J. 2010, 7:71.
71. Leroux-Roels I., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 2007, 370:580-589.
72. Li K.S., et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004, 430:209-213.
73. Lin Y.P., et al. Avian-to-human transmission of H9N2 subtype influenza A viruses: Relationship between H9N2 and H5N1 human isolates. Proc. Natl. Acad. Sci. USA 2000, 97:9654-9658.
74. Lin J., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: A phase I randomised controlled trial. Lancet 2006, 368:991-997.
75. Lipatov A.S., et al. Influenza: Emergence and control. J. Virol. 2004, 78:8951-8959.
76. Lipatov A.S., et al. Pathogenesis of Hong Kong H5N1 influenza virus NS gene reassortants in mice: The role of cytokines and B- and T-cell responses. J. Gen. Virol. 2005, 86:1121-1130.
77. Lipsitch M., et al. How to maintain surveillance for novel influenza A H1N1 when there are too many cases to count. Lancet 2009, 374:1209-1211.
78. Lopez-Cervantes M., et al. On the spread of the novel influenza A (H1N1) virus in Mexico. J. Infect. Dev. Ctries. 2009, 3:327-330.
79. Lowen A.C., et al. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog. 2007, 3:1470-1476.
80. Lu X., et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 2006, 24:6588-6593.
81. Lu J.H., et al. Highlight the significance of genetic evolution of H5N1 avian flu. Chin. Med. J. Engl. 2006, 119:1458-1464.
82. McAuley J.L., et al. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2007, 2:240-249.
83. McAuley J.L., et al. The effects of influenza A virus PB1-F2 protein on polymerase activity are strain specific and do not impact pathogenesis. J. Virol. 2010, 84:558-564.
84. McCarthy M.W., Kockler D.R. Trivalent intranasal influenza vaccine, live. Ann. Pharmacother. 2004, 38:2086-2093.
85. McCauley J.W., Mahy B.W. Structure and function of the influenza virus genome. Biochem. J. 1983, 211:281-294.
86. McCullers J.A., Van De Velde L.A., Allison K.J., Branum K.C., Webby R.J., Flynn P.M. Recipients of vaccine against the 1976 "Swine Flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin. Infect. Dis. 2010, 50(11):1487-1492.
87. Minor P.D., et al. Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009, 27:2907-2913.
88. Mosca F., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. USA 2008, 105:10501-10506.
89. Napolitano L.M., et al. Nonventilatory strategies for patients with life-threatening 2009 H1N1 influenza and severe respiratory failure. Crit. Care Med. 2010, 38:e74-e90.
90. Nayak D.P., et al. Assembly and budding of influenza virus. Virus Res. 2004, 106:147-165.
91. Neumann G., et al. H5N1 influenza viruses: Outbreaks and biological properties. Cell Res. 2010, 20:51-61.
92. Nguyen-Van-Tam J.S., Hampson A.W. The epidemiology and clinical impact of pandemic influenza. Vaccine 2003, 21:1762-1768.
93. Nichol K.L., Treanor J.J. Vaccines for seasonal and pandemic influenza. J. Infect. Dis. 2006, 194(Suppl. 2):S111-S118.
94. Nicholson K.G., et al. Influenza. The Lancet 2003, 362:1733-1745.
95. Novartis Novartis on track to deliver Influenza A (H1N1) vaccine for the US http://www.nibr.novartis.com/newsroom/media-releases/en/2009/1351038.shtml.
96. ® http://hugin.info/134323/R/1132639/211845.pdf.
97. Novartis Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility http://www.novartis.com/newsroom/media-releases/en/2009/1356789.shtml.
98. Novel Swine-Origin Influenza A Virus Investigation Team Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 2009, 360:2605-2615.
99. Oshitani H., et al. Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg. Infect. Dis. 2008, 14:875-880.
100. Peiris M.S. Avian influenza viruses in humans. Rev. Sci. Tech. 2009, 28:161-173.
101. Peiris M., et al. Human infection with influenza H9N2. Lancet 1999, 354:916-917.
102. Peiris J.S., et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004, 363:617-619.
103. st century. Eur. J. Immunol. 2009, 39:2946-2954.
104. Peiris J.S.M., et al. Innate immune responses to influenza A H5N1: Friend or foe?. Trends Immunol. 2009, 30:574-584.
105. Pinto L.H., Lamb R.A. The M2 proton channels of influenza A and B viruses. J. Biol. Chem. 2006, 281:8997-9000.
106. Plennevaux E., et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: A preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
107. Poon L.L., et al. Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice. J. Immunol. 2009, 182:3063-3071.
108. Prabhu N., et al. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J. Virol. 2009, 83:2553-2562.
109. Prieto-Lara E., Mendez A.L. Safety and immunogenicity of prepandemic H5N1 influenza vaccines: A systematic review of the literature. Vaccine 2010, 28(26):4328-4334.
110. Rao S.S., et al. Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret. PLoS ONE 2010, 5:e9812.
111. Renegar K.B. Influenza virus infections and immunity: A review of human and animal models. Lab. Anim. Sci. 1992, 42:222-232.
112. Rimmelzwaan G.F., McElhaney J.E. Correlates of protection: Novel generations of influenza vaccines. Vaccine 2008, 26(Suppl. 4):D41-D44.
113. Rothberg M.B., Haessler S.D. Complications of seasonal and pandemic influenza. Crit. Care Med. 2010, 38:e91-e97.
114. Sawada T., et al. Influenza viral hemagglutinin complicated shape is advantageous to its binding affinity for sialosaccharide receptor. Biochem. Biophys. Res. Commun. 2007, 355:6-9.
115. Schaffer F.L., et al. Survival of airborne influenza virus: Effects of propagating host, relative humidity, and composition of spray fluids. Arch. Virol. 1976, 51:263-273.
116. Schotsaert M., et al. Universal M2 ectodomain-based influenza A vaccines: Preclinical and clinical developments. Expert Rev. Vaccines 2009, 8:499-508.
117. Shaw M.W., et al. New aspects of influenza viruses. Clin. Microbiol. Rev. 1992, 5:74-92.
118. Shinde V., et al. Triple-reassortant swine influenza A (h1) in humans in the United States, 2005-2009. N. Engl. J. Med. 2009, 360:2616-2625.
119. Shinya K., et al. PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology 2004, 320:258-266.
120. Shortridge K.F., et al. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 1998, 252:331-342.
121. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu. Rev. Biochem. 2000, 69:531-569.
122. Skountzou I., et al. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 2010, 28(24):4103-4112.
123. Smith G.J.D., et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459:1122-1125.
124. Smith G.J., et al. Dating the emergence of pandemic influenza viruses. Proc. Natl. Acad. Sci. USA 2009, 106:11709-11712.
125. Snacken R., et al. The next influenza pandemic: Lessons from Hong Kong, 1997. Emerg. Infect. Dis. 1999, 5:195-203.
126. Spreafico R., et al. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur. J. Immunol. 2010, 40:638-642.
127. Stephenson I., Nicholson K.G. Influenza: Vaccination and treatment. Eur. Respir. J. 2001, 17:1282-1293.
128. Stephenson I., et al. Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003, 362:1959-1966.
129. Sui J., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 16:265-273.
130. Suzuki Y. Sialobiology of influenza: Molecular mechanism of host range variation of influenza viruses. Biol. Pharm. Bull. 2005, 28:399-408.
131. Swedish K.A., et al. First season of 2009 H1N1 influenza. Mt. Sinai J. Med.: J. Transl. Person. Med. 2010, 77:103-113.
132. Szretter K.J., et al. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J. Virol. 2007, 81:2736-2744.
133. Talon J., et al. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J. Virol. 2000, 74:7989-7996.
134. Tang J.W., et al. Features of the new pandemic influenza A/H1N1/2009 virus: Virology, epidemiology, clinical and public health aspects. Curr. Opin. Pulm. Med. 2010, 16:235-241.
135. Taubenberger J.K., et al. Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001, 356:1829-1839.
136. Thompson W.W., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
137. Tosh P.K., et al. Influenza vaccines: From surveillance through production to protection. Mayo Clin. Proc. 2010, 85:257-273.
138. Tritto E., et al. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009, 27:3331-3334.
139. Tu W., et al. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J. Virol. 2010, 84(13):6527-6535.
140. Tumpey T.M., et al. Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J. Virol. 2000, 74:6105-6116.
141. Tumpey T.M., et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: Functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J. Virol. 2005, 79:14933-14944.
142. Ulmer J.B., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
143. Uyeki T.M. Human infection with highly pathogenic avian influenza A (H5N1) virus: Review of clinical issues. Clin. Infect. Dis. 2009, 49:279-290.
144. Vajo Z., et al. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010, 375:49-55.
145. Wan H., et al. Replication and transmission of H9N2 influenza viruses in ferrets: Evaluation of pandemic potential. PLoS ONE 2008, 3:e2923.
146. Wang C., et al. Ion channel activity of influenza A virus M2 protein: Characterization of the amantadine block. J. Virol. 1993, 67:5585-5594.
147. Wang X., et al. Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J. Virol. 2000, 74:11566-11573.
148. WHO A review of production technologies for influenza virus vaccines, and their suitability for deployment in developing countries for influenza pandemic preparedness 2006, http://www.who.int/vaccine_research/diseases/influenza/Flu_vacc_manuf_tech_report.pdf.
149. WHO Use of Cell Lines for the Production of Influenza Virus Vaccines: An Appraisal of Technical, Manufacturing, and Regulatory Considerations http://www.who.int/vaccine_research/diseases/influenza/WHO_Flu_Cell_Substrate_Version3.pdf.
150. WHO Pandemic (H1N1) 2009 http://www.who.int/csr/disease/swineflu/en/index.html.
151. WHO Strategic Advisory Group of Experts on Immunization - report of the extraordinary meeting on the influenza A (H1N1) 2009 pandemic. Wkly. Epidemiol. Rec. 2009, 84:301-308.
152. WHO Pandemic influenza A (H1N1) 2009 virus vaccine-conclusions and recommendations from the October 2009 meeting of the immunization strategic advisory group of experts http://www.who.int/csr/disease/swineflu/meetings/sage_oct_2009/en/index.html.
153. WHO http://www.who.int/csr/disease/avian_influenza/country/cases_table_2010_04_21/en/index.html.
154. WHO Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines http://www.who.int/csr/disease/avian_influenza/guidelines/h5n1virus/en/.
155. Wong J.P., et al. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 2009, 27:3481-3483.
156. Wright P.F. Vaccine preparedness-are we ready for the next influenza pandemic?. N. Engl. J. Med. 2008, 358:2540-2543.
157. Wu F., et al. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine 2009, 27:4320-4324.
158. Xing Z., et al. Host immune and apoptotic responses to avian influenza virus H9N2 in human tracheobronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 2010, 10.1165/rcmb.2009-0120OC.
159. Yen H.L., Webster R.G. Pandemic influenza as a current threat. Curr. Top. Microbiol. Immunol. 2009, 333:3-24.
160. Yewdell J., Garcia-Sastre A. Influenza virus still surprises. Curr. Opin. Microbiol. 2002, 5:414-418.